Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And …

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And Migraine ProgramsDetails Category: More News Published on Wednesday, 02 September 2015 10:11 Hits: 60 Global Co-Development and Co-Commercialization Agreement in Alzheimer’s Disease With Novartis’ Phase 1/2a BACE Inhibitor as the Lead Preventative Treatment Approach Directed at Genetically Predisposed Individuals at Risk of Developing Alzheimer’s Disease; Builds on Amgen’s Genetic Validation Strategy Global Co-Development Agreement More Rapidly Advances Amgen’s Migraine Programs, Including AMG 334 in Phase 3 Amgen Retains Migraine Commercialization Rights in the U.S., Japan and Canada; Provides Novartis With Rights to Commercialize Migraine Programs in Europe and Rest of World; Leverages Novartis’ Strong Commercial Neuroscience Presence THOUSAND OAKS, CA, USA I Sept. 1, 2015 I Amgen (NASDAQ:AMGN) today announced a neuroscience collaboration with Novartis in the areas of…


Link to Full Article: Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And …